← Standard Biotools (LAB)

Standard Biotools SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

  • 8-KNov. 19, 2026, 5 p.m. ETView on SEC.govOur explainer

    Departure/appointment of directors or officers · Submission of matters to a vote of security holders · Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedStandard BioTools stockholders approve Treeline merger share issuance, 1-for-20 to 1-for-40 reverse split and Mass Cytometry sale

  • 8-KNov. 16, 2026, 4:27 p.m. ETView on SEC.gov

    Other events

    AI summary, unreviewedStandard BioTools 8-K supplements Treeline merger proxy after 15 demand letters and two New York complaints; Centerview values company at $1.14 per share vs. $0.62 pre-filing market cap

  • 8-KNov. 3, 2026, 8:23 a.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

    AI summary, unreviewedStandard BioTools Completes Sale of Microfluidics Business to ARCHIMED, Which Will Operate as Biomark Scientific

  • 8-KOct. 5, 2026, 4:16 p.m. ETView on SEC.gov

    Regulation FD disclosure · Financial statements and exhibits

  • 8-KSept. 30, 2026, 5:27 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Termination of a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits

  • 8-KAug. 5, 2026, 4:10 p.m. ETView on SEC.gov

    Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits

  • 8-KJuly 28, 2026, 8:20 a.m. ETView on SEC.gov

    Entry into a material definitive agreement · Regulation FD disclosure · Financial statements and exhibits

  • 8-KJuly 24, 2026, 4:38 p.m. ETView on SEC.gov

    Delisting notice / failure to meet listing standard